The GVHD market is expanding due to increasing transplant procedures and therapeutic advancements. Leading companies like Incyte, Pfizer, and Equillium are pioneering novel JAK inhibitors and targeted therapies that enhance treatment efficacy and reduce steroid dependency. Evolving diagnostic approaches and management guidelines are improving care standards for this serious post-transplant complication.
Access Full Analysis:
https://www.delveinsight.com/i....nfographics/graft-ve
Like
Comment
Share
